Pall — Q3 FY2013 Earnings Presentation
19 slides from Pall's earnings presentation, Jun 4, 2013
Slide 1: Q3 FY 2013 Financial Results
Better Lives. Better Planet.SM © 2013 Pall Corporation Q3 FY 2013 Financial Results May 31, 2013 Exhibit 99.2
Slide 2: Forward-looking statements
2 The matters discussed in this presentation contain “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. Results for the third quarter of fiscal year 2013 are preliminary until the Company's Form 10-Q is filed with the Securities and Exchange Commission o
Slide 3: Conference Call Replay Info
3 Conference Call Replay Info Toll-Free: 855.859.2056 International: 404.537.3406 Conference ID: 72099997 Internet: www.pall.com/investor
Slide 4: Q3 Overview
4 Q3 Overview Continued caution on the macro environment – Asia in particular Q3 year-over-year comparisons easier Operational momentum strong – Customer service levels in good shape – Operating model enabling integration – Cost saving initiatives improving bottom-line – Solid productivity giv
Slide 5: Q3 Financial Summary
5 $658 $641 $- $200 $400 $600 $800 Revenue % Growth Excluding FX FY 2012 FY 2013 Q3 Financial Summary Dollars in millions, except EPS data A reconciliation of Non-GAAP Financial Measures in this presentation to their GAAP Counterparts is provided in the Appendix. 15.0% 17.4% 10.0% 15.0% 20.0% Operat
Slide 6: Q3 Regional Sales & Orders
6 $0 $100 $200 $300 Sales Orders Sales Orders Sales Orders $209 +8% $213 +4% $259 +2% $173 -11% Americas Europe Asia $258 +18% $176 -8% Q3 Regional Sales & Orders Dollars in millions Sales and orders changes exclude FX A reconciliation of Non-GAAP Financial Measures in this presentation to their GAA
Slide 7: Q3 Sales by Segment
7 Life Sciences Consumables $305 +12% Industrial Consumables $266 -1% Industrial Systems $49 -24% Life Sciences Systems $21 -47% 41% 48% 8% 3% Q3 Sales by Segment Dollars in millions Percentages outside pie charts and in box represent sales change excluding FX Percentages inside pie charts represent
Slide 8: Q3 Life Sciences Segment Performance
8 Q3 Life Sciences Segment Performance Dollars in millions A reconciliation of Non-GAAP Financial Measures in this presentation to their GAAP Counterparts is provided in the Appendix Sales Q3 FY 2013 YoY Change YoY Change Excluding FX Consumables $ 305 10% 12% Systems 21 -48% -47% Total Life Science
Slide 9: Q3 Industrial Segment Performance
9 Q3 Industrial Segment Performance Dollars in millions A reconciliation of Non-GAAP Financial Measures in this presentation to their GAAP Counterparts is provided in the Appendix Sales Q3 FY 2013 YoY Change YoY Change Excluding FX Consumables $ 266 -3% -1% Systems 49 -25% -24% Total Industrial $ 31
Slide 10: Q3 Cash Flow and Working Capital
10 Q3 Cash Flow and Working Capital YTD FY13 YTD FY12 Operating Cash Flow 207$ 326$ CapEx (66) (127) Free Cash Flow 141$ 199$ Other Significant Sources/(Uses) of Cash: Pr ceeds from sale of assets 537$ 26$ Acquisition of businesses - (168) Dividends (80) (65) Borrowing/Repayment under Financing Faci
Slide 11: Outlook FY 2013
11 Outlook FY 2013 Sales flat, excluding FX – Life Sciences up mid-single digits – Industrial down mid-single digits 22.5% Tax rate $0.18 - $0.20 of FX headwind* Pro forma EPS: $2.95 - $3.05 A reconciliation of Non-GAAP Financial Measures in this presentation to their GAAP Counterparts is pr
Slide 12: Appendix
Better Lives. Better Planet.SM © 2013 Pall Corporation Appendix
Slide 13: Q3 Earnings and FY 2013 Estimates from Continuing Operations
13 Appendix: Q3 Earnings and FY 2013 Estimates from Continuing Operations Reconciliation of Non-GAAP Financial Measures Diluted EPS from continuing operations as reported 0.65$ 0.60$ 2.98$ Discrete Items: ROTC after pro forma tax effect 0.09 0.01 0.15 Tax Adjustments - - (0.09) Interest Adjustments
Slide 14: Q3 Life Sciences Sales By Market & Technology
14 Appendix: Q3 Life Sciences Sales By Market & Technology Reconciliation of Non-GAAP Financial Measures Q3 FY13 Q3 FY13 Estimated Impact of FX Q3 FY13 Estimate Excluding FX Q3FY12 % Change Excluding FX Consumables Sales: BioPharmaceuticals 208,217$ (4,426)$ 212,643$ 184,702$ 15.1% Food & Beverage 4
Slide 15: Q3 Industrial Sales By Market & Technology
15 Appendix: Q3 Industrial Sales By Market & Technology Reconciliation of Non-GAAP Financial Measures Q3 FY13 Q3 FY13 Estimated Impact of FX Q3 FY13 Estimate Excluding FX Q3 FY12 % Change Excluding FX Consumables Sales: Process Technologies 139,712$ (3,042)$ 142,754$ 151,137$ -5.5% Aerospace 61,465
Slide 16: Q3 Sales by Segment and Region
16 Appendix: Q3 Sales by Segment and Region Reconciliation of Non-GAAP Financial Measures Q3 FY13 Q3 FY13 Estimated Impact of FX Q3 FY13 Estimate Excluding FX Q3 FY12 % Change Excluding FX Life Sciences Sales: Americas 101,994$ (798)$ 102,792$ 95,505$ 7.6% Europe 162,284 (2,249) 164,533 154,527 6.5%
Slide 17: Q3 Orders by Technology
17 Appendix: Q3 Orders by Technology Reconciliation of Non-GAAP Financial Measures Dollars in thousands Q3 FY13 Q3 FY13 Estimated Impact of FX Q3 FY13 Estimate Excluding FX Q3 FY12 % Change Excluding FX Life Sciences Orders: Consumables 299,278$ (6,419)$ 305,697$ 289,561$ 5.6% Systems 35,897 (1,347)
Slide 18: Q3 Operating Profit
18 Appendix: Q3 Operating Profit Reconciliation of Non-GAAP Financial Measures Operating Profit Q3 FY13 Q3 FY12 Life Sciences segment profit 81,195$ 75,386$ Industrial segment profit 45,853 39,431 Total segment profit 127,048$ 114,817$ General corporate expenses (15,172) (16,397) Operating profit 11
Slide 19: www.pall.com/green
Better Lives. Better Planet.SM © 2013 Pall Corporation www.pall.com/green